ISRCTN16774163已完成未知
Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 72
研究概览
简要总结
2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31340842 protocol (added 26/07/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35697571/ (added 15/06/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For recruitment to all study groups:
- •1. Parents/legal guardians are willing and able to comply with the requirements of the trial protocol and have internet access for the duration of the study
- •2. Parents/legal guardians have given informed consent for their child’s participation in the study
- •3. Participant is willing and able to give informed assent for participation in the trial
- •4. In the Investigator’s opinion, participants are able and willing to comply with all trial requirements
- •5. Parents/legal guardians/participants are willing to allow their General Practitioner and consultant, if appropriate, to be notified of participation in the trial
- •For recruitment to study groups 1 to 6 only:
- •Male or female, aged approximately 11 years who have completed a vaccination course of 4CMenB as an infant or toddler in clinical trials V72P6, V72P6E1,V72P9 or V72P9E1
- •For recruitment to naïve groups 7 and 8 only:
- •Male or female, born between 25/06/2006 – 17/12/2006 (age range is matched with group 1-6), who have not previously received 4CMenB vaccine. The aim is to recruit approximately 50% female and 50% male participants, in order to match with the previously vaccinated group
排除标准
- •The participant may not enter the trial if ANY of the following apply:
- •1. Children of parents/legal guardians who are on the delegation log for this study
- •2. History of invasive meningococcal B disease
- •3. History of being a household contact with a case of confirmed bacterial meningitis
- •4. Confirmed or suspected immunodeficiency
- •5. A family history of congenital or hereditary immunodeficiency, or maternal HIV
- •6. History of anaphylactic reaction to any component of the vaccine
- •7. No internet access for the duration of the study
- •8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial
- •9. Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
- •10. Prior or planned receipt of any other investigational vaccine or drug
- •11. Thrombocytopenia or any bleeding disorder
- •12. Receipt of blood, blood products, or plasma derivatives within the past 3 months
- •Exclusion to study groups 1 to 6 only:
- •1. Any previous vaccination with 4CMenB vaccine except as part of V72P6, V72P6E1, V72P9 or V72P9E1 clinical trials
- •2. Any previous vaccination with another meningococcal B vaccine (such as outer membrane vesicle vaccines)
- •3. Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 1 month or long-term systemic corticosteroid therapy (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). However, this may be discussed on a case by case basis. Nasal, topical or inhaled steroids are allowed
- •Exclusion to naïve groups 7 and 8 only:
- •1. Previous vaccination with 4CMenB vaccine or with any other meningococcal B vaccine (such as outer membrane vesicle vaccines)
- •2. Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy
- •3. Current receipt of long-term systemic corticosteroid therapy (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed.
- •4. Long-term prophylactic antibiotic use
- •Temporary exclusions for all study groups:
- •To receiving 4CMenB vaccine:
- •1. Administration of any other vaccine within 14 days before the study vaccines
- •2. Scheduled elective surgery, planned admission or other procedures requiring general anaesthesia within 7 days of receiving 4CMen B vaccine
- •3. Febrile illness (axillary temperature =38°C)
- •4. Significant acute or chronic infection within the previous 7 days, or fever (=38°C) within the previous 3 days
- •For blood draw to be performed:
- •1. Receipt of systemic antibiotics within the previous 7 days
- •2. For participants in groups 1-6 who are unable to cease long-term antibiotics for one week prior to the scheduled study visit, we will not take blood samples for analysis. The trialists will still vaccinate these part
研究者
相似试验
进行中（未招募）
1 期
Meningococcal B Booster Vaccine in Young PeopleMeningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning).EUCTR2017-004732-11-GBniversity of Oxford117
已完成
不适用
Clinical care bundles for adult meningitis in MalawiBacterial meningitisPACTR201111000338157iverpool School of Tropical Medicine200
进行中（未招募）
4 期
Prevention of Pneumonia in Children (age: 2 to 5 years) with HIV Infection.CTRI/2012/03/002515Indian Council of Medical Research300
已完成
不适用
Clinical care Bundles for Adult Meningitis in MalawiISRCTN96218197iverpool School of Tropical Medicine (UK)200
已完成
不适用
A Human Controlled Infection Study with Neisseria Lactamica in Malian AdultsMeningitis, MeningococcalNCT04665791Center for Vaccine Development - Mali55